Longevity & AgingNew Obesity Drug Targets Fat Storage Instead of Appetite in Early Trials
A biotech company called Antag Therapeutics is developing a new obesity drug that works differently from popular GLP-1 treatments like Ozempic. Instead of reducing appetite, AT7687 blocks a receptor linked to how the body stores fat. In a first-in-human study presented at the American Diabetes Association's 2026 conference, the drug was well tolerated, caused no serious side effects, and showed minimal gastrointestinal issues — a common complaint with existing drugs. Early data also showed reductions in LDL cholesterol and resting heart rate. When combined with another weight-loss compound called cagrilintide in primate studies, the pairing produced double-digit weight loss, better insulin sensitivity, and preferential fat loss over muscle — without increasing appetite suppression. The results suggest a fundamentally different approach to obesity treatment.
